MANSFIELD, Mass., July 11, 2024 (GLOBE NEWSWIRE) -- 3Daughters, Inc., a clinical development company fueling evolutionary healthcare for women, announced successful completion of an oversubscribed Seed financing round of $4.7M. This round included participation from existing investors Thairm Bio, Argosy Foundation, Wexford Science and Technology, LLC, UMass Amherst, and new undisclosed investors. Previously, the company had announced the close of the first tranche of this financing round, exceeding $2 million. The additional investor participation underscores the growing significance and need for innovation in Women's Health and particularly for contraception, a growing $8 billion dollar market in the U.S. Women use contraceptives on average for 30 years and improved options are needed. Mary Beth Cicero, CEO of 3Daughters, commented, "We are thrilled by the overwhelming response from both our existing and new investors who share our determination and dedication to improving therapies for women, ...